Polyrizon Documenten
Documenten
0
Ticker
PLRZ
ISIN
IL0011814113
Polyrizon SEC Filings
Type | Bericht | Datum |
|---|---|---|
| Geen documenten beschikbaar | ||
Polyrizon Documenten 2026
Deze pagina bevat alle officiële documenten en SEC-filings voor Polyrizon aandelen (PLRZ, ISIN: IL0011814113). Dit omvat jaarverslagen (Formulier 10-K), kwartaalrapporten (Formulier 10-Q) en insidertransacties (Formulier 4). Momenteel zijn 0 documenten beschikbaar. Gegevens worden regelmatig bijgewerkt om beleggers een volledig overzicht van Polyrizon's regelgevingsfilings te bieden.
Polyrizon Aandelenanalyse
Polyrizon Polyrizon Ltd develops medical device hydrogels delivered as nasal sprays that form a thin barrier in the nasal cavity to block viruses and allergens. The company specializes in creating a biological mask using naturally occurring building blocks, focusing on both product development and commercialization. Medical specialists and researchers collaborate with Polyrizon Ltd to advance their intranasal solutions. The firm's primary revenue comes from the development and commercialization of its nasal spray hydrogel products. These products target healthcare providers and consumers seeking protection against viral and allergen exposure. By forming a shield containment barrier, Polyrizon Ltd offers a solution that complements existing health measures without requiring additional equipment. Polyrizon Ltd's business model centers on the creation of a unique nasal barrier technology. The company leverages its focus on intranasal delivery to address market needs for non-invasive protection. Its collaboration with medical specialists ensures that its products meet clinical standards and user requirements.